Chronic rhinosinusitis with nasal polyps presents a substantial clinical burden, affecting nasal airflow, olfactory function, ...
Treatment with tezepelumab has been effective for sinonasal symptoms in patients with severe, uncontrolled asthma and a ...
Nasal Polyps Treatment Market Research Report The global nasal polyps treatment market is expected to reach around $4,243.9 million by 2030 ...
FDA reviews GSK depemokimab for asthma and CRSwNP, with a decision expected by December 2025. Phase 3 data shows improvements ...
Chronic sinusitis with nasal polyps (CRSwNP) accounts for 20 to 33 percent of these cases. Even after surgical treatment, the ...
The asthma medication reduces congestion in patients with severe, uncontrolled chronic rhinosinusitis with nasal polyps in a ...
With Sunday’s Academy Awards ceremony in the rearview mirror, GSK is looking ahead to a potential blockbuster premiere of its ...
Subsequent nasal-polyp surgery and treatment with systemic glucocorticoids also significantly declined with tezepelumab treatment. Secondary endpoint results "show that the patients had clinically ...
The Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for depemokimab for asthma with type 2 inflammation and chronic rhinosinusitis with nasal polyps ...
Company continues to focus on upcoming results from ENLIGHTEN 2 pivotal Phase 3 trial in CRS patients, expected in 2Q 2025In parallel, the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback